Arginine Vasopressin Enhances Cell Survival via a G Protein–Coupled Receptor Kinase 2/β-Arrestin1/Extracellular-Regulated Kinase 1/2–Dependent Pathway in H9c2 Cells

Weizhong Zhu, Douglas G. Tilley, Valerie D. Myers, Ryan C. Coleman, and Arthur M. Feldman

Cardiovascular Research Center (W.Z., V.D.M., R.C.C.), Departments of Physiology (W.Z., V.D.M., R.C.C., A.M.F.), Pharmacology (D.G.T.), and Medicine (A.M.F.), and Center for Translational Medicine (D.G.T.), Temple University School of Medicine, Philadelphia, Pennsylvania

Received March 15, 2013; accepted May 20, 2013

ABSTRACT

Circulating levels of arginine vasopressin (AVP) are elevated during hypovolemia and during cardiac stress. AVP activates arginine vasopressin type 1A (V1A)/Gq-coupled receptors in the heart and vasculature and V2/Gq-coupled receptors in the kidney. However, little is known regarding the signaling pathways that influence the effects of V1a receptor (V1aR) activation during cellular injury. Using hypoxia-reoxygenation (H/R) as a cell injury model, we evaluated cell survival and caspase 3/7 activity in H9c2 myoblasts after treatment with AVP. Pretreatment of H9c2 cells with AVP significantly reduced caspase 3/7 activity in H9c2 myoblasts after treatment with H/R. AVP-mediated protection against H/R was elicited only via GRK2- and β-arrestin1-dependent signaling. These results suggest that activation of the V1aR in H9c2 cells mediates protective signaling via a GRK2/β-arrestin1/ERK1/2-dependent mechanism that leads to decreased caspase 3/7 activity and enhanced survival under conditions of ischemic stress.

Introduction

Circulating levels of arginine vasopressin (AVP), which are elevated during hypovolemia and during cardiac stress, mediate important physiologic functions such as osmotic regulation, vasoconstriction, and release of adrenocorticotropin hormone. These physiologic effects are mediated through the interaction of AVP with specific membrane G protein–coupled receptors (GPCRs) in different target tissues: arginine vasopressin type 1A receptor (V1A; Gq-coupled; heart and vasculature), V3R (Gq-coupled; renal collecting tubule), and V1bR (Gq-coupled; anterior pituitary), also termed V2R (Lolait et al., 1992; Morel et al., 1992; de Keyzer et al., 1994). Although administration of AVP to neonatal mouse cardiomyocytes has been reported to increase cell hypertrophy (Hiroyama et al., 2007), AVP has variable effects on the heart during injury associated with ischemia and reperfusion (Indrambarya et al., 2009; Nazari et al., 2011). Recently, we found that both constitutive and controlled cardiacspecific overexpression of V1AR induced the development of left ventricular hypertrophy, dilatation, diminished contractile performance, and reprogramming of the heart failure signaling cascade.

vasopressin type 1A receptor (V1AR; Gq-coupled; heart and vasculature), V2R (Gq-coupled; renal collecting tubule), and V1bR (Gq-coupled; anterior pituitary), also termed V2R (Lolait et al., 1992; Morel et al., 1992; de Keyzer et al., 1994). Although administration of AVP to neonatal mouse cardiomyocytes has been reported to increase cell hypertrophy (Hiroyama et al., 2007), AVP has variable effects on the heart during injury associated with ischemia and reperfusion (Indrambarya et al., 2009; Nazari et al., 2011). Recently, we found that both constitutive and controlled cardiacspecific overexpression of V1AR induced the development of left ventricular hypertrophy, dilatation, diminished contractile performance, and reprogramming of the heart failure signaling cascade.

This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grants HL105414 and HL091799]. The project described was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grants HL105414 and HL091799].

dx.doi.org/10.1124/mol.113.086322.

This article has supplemental material available at molpharm.aspetjournals.org.

Supplemental material to this article can be found at:
http://molpharm.aspetjournals.org/content/suppl/2013/05/20/mol.113.086322.DC1

http://dx.doi.org/10.1124/mol.113.086322
Mol Pharmacol 84:227-235, August 2013

ABBREVIATIONS: AT1R, angiotensin type 1A receptor; AVP, arginine vasopressin; βARKct, C-terminal GRK2 peptide; ERK1/2, extracellular-regulated kinase 1/2; β-gal, β-galactosidase; GFP, green fluorescent protein; GRK, G protein–coupled receptor kinase; Gq, Gq-1-ires-GFP; NF, heart failure; H/R, hypoxia/reoxygenation; MEK1/2, mitogen-activated protein kinase; OPC41061, N-4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-benzo[b]azepine-1-carboxyl)-3-methyl-phenyl]-2-methyl-benzamide; PD 98059, 2′-amino-3′-methoxyxavone; P-ERK1/2, ERK1/2 phosphorylation; PKC, protein kinase C; Ro 31-8245/Ro-31, 2-[8-(aminomethyl)-6,7,8,9-tetrahydropropyrolo[1,2-a]indol-3-y]-3-(1-methyl-1H-indol-3-yl)maleimide, HCl, bisindolylmaleimide X, HCl; SSR149415, (2S,4R)-1-[(5-chloro-1-[(2,4-dimethoxyphenyl)sulfonfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-y]-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamido; SR45059, (2S)-1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl)-2-pyrrolidinecarboxamido; V1AR, arginine vasopressin type 1A receptor.
conditions of myocardial stress (Noma et al., 2007; Kim et al., 2011). Indeed, in the heart, GRK5), leading to internalization and desensitization of the V1AR (Innamorati et al., 1998, 1999; Berrada et al., 2000). The GRKs can also alter cellular physiology independent of PKC through phosphorylation-dependent recruitment of β-arrestins and subsequent activation of downstream pathways, including extracellular-regulated kinase 1/2 (ERK1/2) signaling, which can act to inhibit the ubiquitous responses to cell stress including apoptosis (Dorn, 2009; Huang et al., 2011; Tilley, 2011). Indeed, in the heart, G protein–independent signaling has been shown to promote cardioprotection downstream of angiotensin II- and β-adrenergic receptor activation during conditions of myocardial stress (Noma et al., 2007; Kim et al., 2012). These findings led to the development of biased ligands, GPCR antagonists that activate unique G protein–independent pathways. However, the role of GRK/β-arrestin–mediated V1AR signaling in promoting cell survival is unknown. Thus, in the present study, we sought to determine the effects of V1AR/G protein–independent signaling on cell survival and caspase 3/7 activity in H9c2 cells exposed to the stress of hypoxia and reoxygenation. This has become more than an academic interest because of the recent development of V1AV2 receptor antagonists for the treatment of patients with hyponatremia secondary to elevated levels of AVP and HF (Rosner and Ronco, 2010; Gheorghiaie et al., 2012; Zmyli et al., 2013).

Materials and Methods

Penicillin and streptomycin were purchased from Invitrogen (Gaithersburg, MD). AVP (V87879) was from Sigma-Aldrich (St. Louis, MO). 2-[8-(Aminomethyl)-6,7,8,9-tetrahydroprido[1,2-a]indol-3-yl]-3-1-methyl-1H-indol-3-yl)maleimide, HCl, bisindolylmaleimide X, HCl (RO 31-8425) (Ro-31, Cat#507514) and PD 98059 (Cat#513000) were from Calbiochem (San Diego, CA). V1A receptor selective antagonist (25)-1-[[2R,3S]-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxysulfonfonyl)-2,3-di hydroxy-1H-indol-2-yl][carbonyl][2- pyridyl]carboxamide (SR45059) was from Tocris Bioscience (Cat#22310; Minneapolis, MN). V1R receptor selective antagonist (2S,4R)-1-5-chloro-1-(2,4-dimethoxyphenyl)sulfonfonyl-3-(2-methoxyphenyl)-2-oxo-2,3-di hydroxy-1H-indol-3-yl)-4-hydroxy-N-N'-2-pyridylcarboxamide (SR141945) (Cat#1114) and V2 receptor selective antagonist N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydrobenzo[b]azine-1-carboxyl]-3-methyl-phenyl]-2-methylbenzamide (OPC41061) (Cat#41061) were purchased from Axon Medchem (Groningen, The Netherlands). A cell viability assay kit and caspase 3/7 assay kit were purchased from Promega (Madison, WI). The hypoxia chamber was purchased from Billups-Rothenberg, Inc. (Del Mar, CA). M199 and Opti-MEM I reduced serum medium were purchased from Invitrogen. Silencer fluorescein-labeled negative control siRNA (AM4620; Ambion/Life Technologies, Carlsbad, CA), GRK2 siRNA (AM16708; Ambion/Life Technologies), GRK5 siRNA (L-080156; Thermo Scientific, Waltham, MA) were from Ambion/Life Technologies. Adenovirus containing β-galactosidase (β-gal) and green fluorescent protein (GFP) were obtained from Dr. Yiben Wang (University of California, Los Angeles). Gq/I-ires-GFP (Gq) and C-terminal GRK2 peptide (βARKet) were obtained from Dr. Satoru Eguchi and Dr. Walter Koch (Temple University, Philadelphia, PA), respectively. Anti-phosphorylated ERK1/2 (anti–P-ERK1/2), anti–total-ERK1/2, anti–β-arrestin1/2, and anti–glyceraldehyde-3-phosphate dehydrogenase antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-GFP, anti-GRK2, and anti-GRK5 were from Santa Cruz Biotechnology (Santa Cruz, CA).

Cell Culture and Adenovirus. H9c2 cells were purchased from American Type Culture Collection (Rockville, MD); maintained in M199 supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 10 μg/ml streptomycin; and grown in an atmosphere of 5% CO2/95% humidified air at 37°C on 6-well plates, 100,000 cells seeded per well. Adenoviral infection with βARKet versus β-galactosidase control (Zhu et al., 2001) or Gq-I-ires-GFP versus GFP control was performed at 100% multiplicity of infection when cell confluence reached 60–70%. Twenty-four to thirty-six hours after infection, cells were treated with the reagents under normal conditions or following hypoxia/reoxygenation (H/R).

Transfection of siRNA. Cells (1 x 105 and 5000 cells per well in 6-well and 96-well plates, respectively) were seeded in plates incubated in M199 with 10% fetal bovine serum. When cell confluence reached 50–60%, the medium was replaced by 1800 μl (6-well plate) or 60 μl (96-well plate) of Opti-MEM I reduced serum medium. The negative control siRNA fluorescein (2.4 μg in 100 μl of Opti-MEM I per well in a 6-well plate and 0.083 μg in 3.2 μl of Opti-MEM I per well in a 96-well plate) and the same amount of scrambled, GRK2, GRK5, and β-arrestin1 siRNA were mixed with the same volume of transfection reagent diluted with Opti-MEM. The mixture (200 and 20 μl per well in 6-well and 96-well plates, respectively) was added to the cells according to the instructions (at a final concentration of 100 nM). The protein levels of GRK2, GRK5, and β-arrestin1 were determined by Western blot at 48–96 hours after transfection, as indicated.

Hypoxia/Reoxygenation. A total of 5000 cells per well were seeded in 96-well plates. When the cell confluence reached 80–90%, cells were starved with fetal calf serum–free medium overnight. Prior to H/R, the cells were pretreated with specific reagents, and the culture cell plates were placed in the hypoxia chamber. The chamber was sealed and aerated with 5% CO2 and 95% nitrogen at 3 l/min for 30 minutes. The cells were maintained in the hypoxic environment for 24 hours at 37°C, and then the cells were reoxygenated for 24 hours with 5% CO2/95% humidified air.

Cell Viability and Caspase 3/7 Assay. Subconfluent cultures grown in 96-well plates with no prior interventions, or infection with adenovirus or transfection with siRNA, as indicated, were starved by withdrawing serum for at least 6 hours. After serum starvation, cells were pretreated with 10 μM to 0.1 μM of vasopressin for 30 minutes in the presence or absence of pharmacological agents, as indicated. Cells were then incubated in the hypoxia chamber for 24 hours followed by reoxygenation for 24 hours. The relative number of live cells and caspase 3/7 activity were measured following the manufacturer’s instructions. Within each assay, triplicates were performed for each condition to attain a single n value.

Immunoblot Analysis of Phosphorylated ERK1/2. After cells were treated for 2–60 minutes with 1 nM to 10 μM AVP, they were rapidly washed two times with ice-cold phosphate-buffered saline and lysed with 250 μl of ice-cold lysis buffer (50 mM Tris-HCl, 1 mM EGTA, 150 mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml leupeptin, 20 mg/ml aprotinin, 1 mM NaF, and 1 mM Na3VO4). After centrifugation at 13,000g for 10 minutes, equal amounts of total cell lysate (20 μg of protein) were subjected to 4–12% SDS-PAGE, followed by immunoblotting for phosphorylated ERK1/2 (1:1000), total ERK1/2 (1:1000), or GFP (1:200). Total ERK1/2 was used to normalize P-ERK1/2 responses.

Statistical Analysis. A commercial software package was used for statistical analysis (GraphPad Software Inc., La Jolla, CA). Comparison of means ± S.E. were compared by unpaired t test, one-, or two-way analysis of variance followed by Tukey’s post-hoc analysis, as indicated in the figure legends. A value of P < 0.05 was
considered statistically significant. The number of independent experiments performed in each assay is indicated in the figure legends.

**Results**

**AVP Protects H9c2 Cells against Hypoxia/Reoxygenation-Induced Cell Death via V₁AR- and ERK1/2-Dependent Signaling.** To test the ability of AVP to mediate protective signaling, we established an in vitro model of cellular stress wherein H9c2 myoblasts, derived from embryonic rat ventricle, underwent hypoxia for 24 hours followed by reoxygenation for 24 hours (H/R). Under normoxic and serum-free conditions, H9c2 cell survival decreased and caspase 3/7 activity increased, responses that were significantly enhanced when the cells underwent H/R (Fig. 1, A and B). Under normoxic and serum-free conditions, the addition of 10% fetal calf serum was sufficient to prevent these responses under either normoxic or H/R conditions. Since H/R performed in the absence of serum induced the most significant alteration in H9c2 cell survival and caspase 3/7 activity under conditions of H/R, we used these conditions for all subsequent experiments. As seen in Fig. 1C, pretreatment of the H9c2 cells with AVP significantly attenuated the H/R-induced changes in both cell survival and caspase 3/7 activity in a concentration-dependent manner.

To confirm the role of the cardiac-expressed AVP receptor (V₁AR) in mediating AVP-dependent protection against cell death, H9c2 cells underwent H/R in the presence or absence of AVP (10 nM) and the V₁AR selective antagonist, SR49059 (0.1 μM). Antagonism of V₁AR with SR49059 abolished the ability of AVP to reduce both caspase 3/7 activity and cell death (Fig. 1, D and E). Neither V₁BR- nor V₂R-selective antagonists (SSR14941 and OPC41061, respectively) had an effect on AVP-dependent changes in caspase 3/7 activity or cell survival during H/R (Supplemental Fig. 1, A and B). Additionally, to assess the potential role of mitogen-activated protein kinase (MEK1/2)-ERK1/2 signaling in mediating the protective effect of AVP, H9c2 cells were treated with the MEK1/2 inhibitor 2-amino-3-methoxyflavone (PD98059) (10 μM) prior to H/R induction. Inhibition of MEK1/2 completely blocked the AVP-mediated effects on cell survival and caspase 3/7 activity (Fig. 1, D and E).
P-ERK1/2 were 0.38 ± 0.08, 104.4 ± 10.2, and 374.9 ± 23.4 nM, respectively (Fig. 2, C and D). ERK1/2 signaling often persists long after receptor stimulation, therefore we assessed the P-ERK1/2 response to AVP at both acute (2–10 minutes) and prolonged (30–60 minutes) time points. AVP-induced P-ERK1/2 peaked at 5 minutes, and was sustained at ~50% peak activation even to 60 minutes poststimulation (Fig. 2, E and F). As expected, pretreatment of H9c2 cells with the MEK1/2 inhibitor PD98059 (10 μM) significantly attenuated both the acute and prolonged P-ERK1/2 responses to AVP stimulation. Thus far, these results demonstrate that V1AR stimulation enhances H9c2 cell survival via MEK1/2-ERK1/2 signaling.

**Inhibition of Goq Protein/PKC Signaling Blunts the AVP-Induced Acute P-ERK1/2 Response but Has No Effect on the AVP-Induced Cell Survival Response.**

GPCR stimulation induces the simultaneous activation of both G protein–dependent and –independent signaling pathways that can each act to modulate ERK1/2 activity (Tilley, 2011). Since V1AR/Goq protein coupling induces the activation of PKC, regulating the hypertrophic gene program (Li et al., 2011), we tested whether Goq protein/PKC–mediated signaling is involved in AVP-induced P-ERK1/2 and cell survival responses. Overexpression of the peptide inhibitor of Goq (Gqi) inhibited the acute P-ERK1/2 response to AVP (2 and 5 minutes, by 90% ± 3% and 52% ± 6%, respectively, versus GFP control), but had no effect on the AVP-induced prolonged responses at 30 and 60 minutes (Fig. 3, A and C). Further, suppression of Goq protein by Gqi overexpression did not impact AVP-induced effects on caspase 3/7 activity or cell survival (Fig. 3, D and E). Similarly, pretreatment of H9c2 cells with the PKC inhibitor Ro-31 (1 μM) inhibited acute phosphorylation of ERK1/2 (90% ± 6% and 62% ± 3% inhibition at 2 and 5 minutes, respectively), but had no effect on persistent ERK1/2 phosphorylation (30–60 minutes) (Fig. 3, B and C). Pretreatment of H9c2 cells with Ro-31 prior
to H/R led to a significant enhancement of H/R-induced cell death and caspase 3/7 activity (Supplemental Fig. 1C). Interestingly, despite the enhanced negative effect on survival mediated by chronic inhibition of PKC by Ro-31, AVP was still capable of inducing a concentration-dependent reduction in cell death and caspase 3/7 activity (Fig. 3F). These results suggest a Gaq protein/PKC-independent component to V1AR-mediated cell survival signaling.

**Overexpression of βARKct Blunts Persistent AVP-Induced P-ERK1/2 and Abrogates AVP-Mediated H9c2 Cell Survival.** To begin to assess the contribution of G protein–independent signaling to V1AR-mediated P-ERK1/2 and survival responses in H9c2 cells, we overexpressed βARKct, the C-terminal peptide of GRK2 that prevents its recruitment and activation upon GPCR stimulation, or β-gal as a control (Koch et al., 1994; Zhu et al., 2001). Overexpression of βARKct predominantly blunted the persistent P-ERK1/2 responses at 30 and 60 minutes by 45% ± 2% and 39% ± 4%, respectively, versus β-gal control (Fig. 4, A and C). Additionally, AVP-elicited cell survival was completely abolished by overexpression of βARKct (Fig. 4, D and E). Comparison of the effects of the combined inhibition of AVP signaling by simultaneous treatment of H9c2 cells with Ro-31 and βARKct was consistent with these results, as the combination of both Ro-31 and βARKct did not further impact the cell survival responses to AVP (Supplemental Fig. 3).
Fig. 1, D and E). These results suggest a role for GRK2-dependent V1AR signaling in the promotion of ERK1/2 phosphorylation and cell survival under conditions of cellular stress.

siRNA-Mediated Deletion of GRK2 and β-Arrestin1, but Not GRK5, Blunts Persistent AVP-Induced P-ERK1/2 and Cell Survival Responses in H9c2 Cells. To confirm the role of GRK2 in mediating the effects of AVP on persistent ERK1/2 phosphorylation and survival in H9c2 cells, siRNA-mediated knockdown of GRK2 was performed versus a scrambled siRNA control. After a 48-hour knockdown, GRK2 protein expression was significantly reduced by 68.5% (Fig. 5, A and D), at which time point the P-ERK1/2 response to AVP was assessed. Consistent with the effects of βARKct on V1AR-mediated signaling, deletion of GRK2 significantly inhibited the persistent P-ERK1/2 response to AVP (Fig. 5, A and E). After 96 hours, including the H/R assay, GRK2 deletion was shown to impair the ability of AVP to promote H9c2 survival during H/R (Fig. 5, F and G). Of note, the H/R procedure did not alter siRNA-mediated silencing of GRK2 in the presence or absence of AVP (Supplemental Fig. 2, A and B).

Via immunoblotting analysis, β-arrestin1 was shown to be the predominant β-arrestin isoform expressed in H9c2 cells (Supplemental Fig. 3A). To determine if there was a low level of β-arrestin2 expression that mediated V1AR effects on ERK1/2 activity and survival responses (Fig. 5, F and G) to AVP were altered in comparison with the scrambled siRNA controls.

β-Arrestins are recruited to GRK-phosphorylated GPCR to induce a number of cellular processes, including persistent ERK1/2 activation, and have been shown to promote cardiac protection under conditions of stress (Luttrell et al., 2001; Noma et al., 2007; Kim et al., 2012). Thus, we sought to determine whether β-arrestins are required for the V1AR/GRK2-dependent effects on ERK1/2 and survival signaling. We began by transfecting the cells with β-arrestin1-selective versus scrambled siRNA. Forty-eight hours later, β-arrestin1 protein expression was significantly reduced by 79.5% (Fig. 5, C and D). As observed with GRK2 knockdown, deletion of β-arrestin1 inhibited the AVP-induced P-ERK1/2 response, again primarily at the persistent (30–60 minutes) time points (Fig. 5, C and E). Further, β-arrestin1 knockdown significantly impaired the ability of AVP to promote H9c2 cell survival and decrease caspase 3/7 activity during H/R (Fig. 5, F and G).

Fig. 4. Overexpression of βARKct blunts persistent AVP-induced P-ERK1/2 and abrogates AVP-mediated H9c2 cell survival. (A) Overexpression of βARKct (versus β-gal) significantly blunted the ERK1/2 phosphorylation response (from 10 to 60 minutes) following AVP stimulation. (B) The averaged data of (A). *P < 0.05; **P < 0.01 versus the same time point (unpaired t test). Overexpression of βARKct significantly blocked the AVP-dependent decrease in caspase 3/7 activity (C) and increase in cell survival (D). *P < 0.05 versus vehicle (phosphate-buffered saline; PBS)-stimulated β-gal control (one-way analysis of variance). All data are presented as the mean ± S.E.M. from three independent experiments. RLU, relative luminescence units; T-ERK1/2, total ERK1/2.
and survival responses (Supplemental Fig. 3, B–E), essentially recapitulating the data attained using β-arrestin1 siRNA. Altogether, these results reveal that under conditions of hypoxic stress, engagement of a V1AR/GRK2/β-arrestin1–mediated signaling pathway in H9c2 cells promotes survival.

Fig. 5. siRNA-mediated deletion of GRK2 and β-arrestin1, but not GRK5, blunts persistent AVP-induced P-ERK1/2 and cell survival responses in H9c2 cells. Representative immunoblots showing GRK2 (A), GRK5 (B), and β-arrestin1 (βarr1) (C) protein expression after siRNA transfection and the corresponding ERK1/2 phosphorylation responses to AVP stimulation (10 nM, 0–60 minutes) in H9c2 cells. (D) The averaged data of GRK2, GRK5, or β-arrestin1 knockdown, compared with scrambled (Scr) siRNA. **P < 0.01 versus scrambled siRNA control [one-way analysis of variance (ANOVA)]. (E) Summary of the effects of siRNA-mediated deletion of GRK2, GRK5, and βarr1 on the P-ERK1/2 response to AVP (10 nM, 0–60 minutes). **P < 0.01 (GRK2 siRNA); ††P < 0.01 (βarr1 siRNA) versus scrambled siRNA at the same time point (unpaired t test). The effects of siRNA-mediated knockdown of GRK2, GRK5, or βarr1 on AVP-mediated caspase 3/7 activity (F) and cell survival (G) during H/R in H9c2 cells are shown. *P < 0.05 GRK2 siRNA versus Scr siRNA (cell survival, caspase 3/7 activity); †P < 0.01 βarr1 siRNA versus Scr siRNA (caspase 3/7 activity); and ††P < 0.05 βarr1 siRNA versus Scr siRNA (cell survival) (repeated two-way ANOVA). All data are presented as the mean ± S.E.M. of three independent experiments. RLU, relative luminescence units.
Discussion

G protein–independent signaling through GRKs and β-arrestins has been shown to mediate a number of beneficial effects on cardiac function and survival during heart failure (Tilley, 2011). GRKs were initially identified as desensitizing regulators of GPCRs, terminating their acute signaling responses to agonist stimulation via phosphorylation of the C-terminal tail of the receptor (Benovic et al., 1986; Hausdorff et al., 1990). It has since been clearly demonstrated that beyond desensitization, GRK also initiates G protein–independent signaling events that act to regulate ERK1/2 activity, for instance, via the recruitment of the scaffolding proteins β-arrestins through differential phosphorylation of GPCRs (Heitzler et al., 2012). These events commonly promote more persistent ERK1/2 activity than that mediated by G proteins, and have been demonstrated to impact numerous cellular processes, including regulation of apoptosis and cell survival in numerous cells and, importantly, in the heart (Dorn, 2009; Tilley, 2011; Huang et al., 2011). Although relatively little is known about the pathophysiologic effects of cardiac-expressed V1AR, our recent study utilizing transgenic mice with inducible cardiac-restricted overexpression of V1AR was the first to conclusively demonstrate that enhanced V1AR signaling in the heart itself directly leads to the development of left ventricular hypertrophy, dilatation, diminished contractile performance, and reprogramming of the HF gene profile in a Goq protein–dependent manner (Li et al., 2011), although a role for Goq protein–independent signaling in the control of cardiac function and/or survival was not investigated.

In the present study, using H9c2 myoblasts as an in vitro model of H/R, we demonstrate that AVP enhances cell survival during stress in a V1AR/GRK2/β-arrestin1/ERK1/2–dependent manner. H9c2 myoblasts, derived from embryonic rat ventricle, were an excellent model system in which to determine its effects on survival, without the confounding presence of other growth- and survival-promoting factors, and the underlying mechanisms, in this case through G protein–independent regulation of ERK1/2. Our finding that V1AR-mediated cell survival is mediated via G protein–independent regulation of ERK1/2 activity is consistent with other reports describing the molecular mechanisms of GPCR-induced survival signaling, including the cardiac-expressed β-adrenergic receptors and the angiotensin type 1A receptor (AT1R) (Noma et al., 2007; Kim et al., 2012). As with the V1AR, the AT1R is a Goq-coupled receptor, and studies have shown the survival signaling response to AT1R stimulation depends not on rapid Goq protein–mediated ERK1/2 signaling, but on prolonged GRK/β-arrestin–mediated ERK1/2 signaling (Ahn et al., 2009; Kim et al., 2012). Our data demonstrate that this pattern of ERK1/2 activation is similar for V1AR in H9c2 myoblasts, wherein Goq protein/PKC–dependent signaling mediates the acute P-ERK1/2 response, and GRK2–β-arrestin1–dependent signaling primarily regulates the persistent phase of the P-ERK1/2 response. This could account for our previous observation in the V1AR transgenic mice that, although inhibition of Goq protein blocked the development of the heart failure phenotype, it only partially inhibited activation of ERK1/2 (Li et al., 2011). Thus, although ERK1/2 signaling is required for the AVP-mediated survival response, the G protein–dependent cohort did not contribute to this effect, implying the need for selective subcellular targeting of V1AR/GRK2/β-arrestin1/ERK1/2 signaling in promoting survival.

A distinctive finding in our study is that GRK2, not GRK5, is responsible for driving the β-arrestin1/ERK1/2–signaling response to AVP, whereas previous studies have found that GRK2 mainly induces GPCR desensitization while other GRK isoforms, including GRK5, are responsible for mediating β-arrestin–dependent ERK1/2 signaling responses (Noma et al., 2007; Heitzler et al., 2012). This is an important finding, as inhibition of GRK2 has been shown to be cardioprotective in models of heart failure (Lymeropoulos et al., 2012), but could limit the ability of V1AR to exert survival signaling. In fact, in light of our findings, inhibition of GRK2 could potentially exacerbate negative V1AR-mediated effects by preventing receptor desensitization and augmenting deleterious Goq protein–dependent signaling during heart failure, in which there are elevated levels of circulating AVP. Additionally, β-arrestin1 and β-arrestin2 are usually ubiquitously expressed and can have redundant or opposing effects on receptor internalization or signaling processes. Thus, our finding that H9c2 cells predominantly express β-arrestin1 with no detectable β-arrestin2 expression is unique, and although in this system β-arrestin1 clearly plays an essential role in mediating the protective effects of V1AR signaling, the contribution of β-arrestin2 to these effects in other cell types, such as fully differentiated adult cardiomyocytes, should be examined on a case-by-case basis.

The importance of understanding the relative contributions of both G protein–dependent and –independent pathways in the regulation of cell survival mechanisms has been recently highlighted in a number of studies investigating biased GPCR ligands, that is, ligands that have agonist-like effects but that are biased toward the activation of one particular pathway over another. A number of AT1R-biased agonists that lack the ability to activate Goq protein–dependent signaling but do promote GRK/β-arrestin–dependent ERK1/2 signaling have been shown capable of regulating apoptotic pathways in vitro and enhancing cardiac contractility and improved cardiac performance in vivo, one of which is undergoing phase II...
evaluation for the treatment of heart failure (Violin et al., 2010; Boerrigter et al., 2011). Late-stage heart failure is often associated with high levels of AVP, which has been associated with symptomatic hypotension and increased mortality (Francis et al., 1990; Gheorghiade et al., 2012). However, the V2-selective antagonist tolvaptan had no effect on survival and actually increased circulating levels of AVP (Lanfear et al., 2013), whereas the V2-selective antagonist lixivaptan was associated with increased mortality in patients hospitalized with acute heart failure and hyponatremia (Xu, 2012; http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenal-DrugsAdvisoryCommittee/UCM318867.pdf). The present data suggest that the use of a biased ligand that blocks both V2-R and V1A-R-Gαq protein–dependent signaling, while at the same time activating V1A-R-mediated GRK2/β-arrestin signaling, would provide a novel therapeutic strategy for acute heart failure with chronic heart failure and elevated levels of AVP.

Acknowledgments

The authors thank Dr. Satoru Eguchi (Temple University School of Medicine) for kindly providing the Gq-Ires-GFP adrenergus.

Authorship Contributions

Participated in research design: Zhu, Tilley, Myers. Conducted experiments: Zhu, Myers, Coleman. Performed data analysis: Zhu, Tilley, Myers, Feldman. Wrote or contributed to the writing of the manuscript: Zhu, Tilley, Feldman.

References


Peptides 32:2459–2466.


V1a-R-Mediated Protection against Hypoxic Stress 235

V14-R-Mediated Protection against Hypoxic Stress 235

V1A-R-Gαq protein–dependent signaling, would provide a novel therapeutic strategy for acute heart failure with chronic heart failure and elevated levels of AVP.

Acknowledgments

The authors thank Dr. Satoru Eguchi (Temple University School of Medicine) for kindly providing the Gq-Ires-GFP adrenergus.

Authorship Contributions

Participated in research design: Zhu, Tilley, Myers. Conducted experiments: Zhu, Myers, Coleman. Performed data analysis: Zhu, Tilley, Myers, Feldman. Wrote or contributed to the writing of the manuscript: Zhu, Tilley, Feldman.

References


Peptides 32:2459–2466.


V14-R-Mediated Protection against Hypoxic Stress 235

V1A-R-Mediated Protection against Hypoxic Stress 235

Address correspondence to: Dr. Weizhong Zhu, Cardiovascular Research Center, Department of Physiology, Temple University School of Medicine, 3500 N. Broad St., Philadelphia, PA 19140. E-mail: weizhong.zhu@temple.edu or Dr. Douglas G. Tilley, Center for Translational Medicine, Department of Pharmacology, Temple University School of Medicine, 3500 N. Broad St., Philadelphia, PA 19140. E-mail: douglas.tilley@temple.edu